Source-grounded facts extracted from Pacira BioSciences, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Pacira BioSciences, Inc. shareholders approved Approval of the Company’s Amended and Restated 2014 Employee Stock Purchase Plan at the 2026-06-09 meeting.
“Proposal 5 — Approval of the Company’s Amended and Restated 2014 Employee Stock Purchase Plan. For Against Abstain Broker Non-Votes 29,089,928 3,497,653 55,974 452,437”
Pacira BioSciences, Inc. shareholders rejected Approval of the Company’s Amended and Restated 2011 Stock Incentive Plan at the 2026-06-09 meeting.
“Proposal 4 — Approval of the Company’s Amended and Restated 2011 Stock Incentive Plan. For Against Abstain Broker Non-Votes 14,178,418 18,405,754 59,383 452,437”
Pacira BioSciences, Inc. shareholders approved Advisory vote to approve the compensation of the Company’s named executive officers at the 2026-06-09 meeting.
“Proposal 3 — Advisory vote to approve the compensation of the Company’s named executive officers. For Against Abstain Broker Non-Votes 19,513,224 13,073,321 57,010 452,437”
Pacira BioSciences, Inc. shareholders approved Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-09 meeting.
“Proposal 2 — Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. For Against Abstain 32,908,044 138,246 49,702”
Pacira BioSciences, Inc. shareholders approved Election of three Class III directors at the 2026-06-09 meeting.
“Proposal 1 — Election of three Class III directors to hold office until the 2029 annual meeting of stockholders, and until their respective successors have been duly elected and qualified. Company’s Nominees Nominee: For Withhold Christopher J. Christie 24,963,961 7,675,321 Samit Hirawat 27,950,304 4,688,937 Thomas Wiggans 28,044,841 4,594,438 DOMA Perpetual Capital Management LLC’s Nominees Nominee: For Withhold Oliver Benton Curtis III 4,614,368 28,024,482 Eric de Armas 4,861,350 27,777,500 Christopher Dennis 4,430,726 28,208,124”
Pacira BioSciences, Inc. reported the first quarter ended March 31, 2026 results: revenue $177.4 million, net income $2.9 million, or $0.07 per share (basic and diluted).
“reference in such a filing. --- EX-99.1 (EX-99.1) --- FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports First Quarter 2026 Financial Results -- Total revenue of $177 million, reflecting increase of 5 percent over first quarter 2025 driven by growth across commercial portfolio, including EXPAREL volume growth of 7 percent -- -- Completed enrollment in”
Pacira BioSciences, Inc. announced a restructuring with charges of approximately $2.4 million to $2.8 million affecting Science Center Campus in San Diego, California (71 employees or approximately 8% of the Company’s total workforce).
“8% of the Company’s total workforce. The Company currently estimates that it will recognize pre-tax charges to its third quarter 2025 financial results of approximately $2.4 million to $2.8 million related to employee termination benefits, consisting of garden leave and severance, healthcare benefits, and, to a lesser extent, other one-time termination”
Pacira BioSciences, Inc.: Adopted majority voting standard for election of director nominees in uncontested elections, retained plurality for contested elections (effective 2025-03-12).
“On March 12, 2025, the Board of Directors of Pacira BioSciences, Inc. (the “Company”) approved and adopted the Third Amended and Restated Bylaws of the Company (the “Third Amended and Restated Bylaws”), effective immediately. The Third Amended and Restated Bylaws reflect the adoption of a majority voting standard for the election of director nominees in uncontested director elections, with a plurality vote standard retained for contested director elections.”
Laura Brege was appointed as Chair of the Board at Pacira BioSciences, Inc..
“the Board, upon recommendation of the Nominating, Governance and Sustainability Committee of the Board, appointed Laura Brege as Chair of the Board, effective as of immediately following the effectiveness of the Resignations.”
Andreas Wicki resigned as Member of the Board at Pacira BioSciences, Inc..
“On January 28, 2025, Paul J. Hastings, Chair of the Board of Directors (the “Board”), and Andreas Wicki, a member of the Board, each notified the Board of Pacira BioSciences, Inc. (the “Company”) of his respective decision to resign as a member of the Board, in each case, effective immediately”
Paul J. Hastings resigned as Chair of the Board at Pacira BioSciences, Inc..
“On January 28, 2025, Paul J. Hastings, Chair of the Board of Directors (the “Board”), and Andreas Wicki, a member of the Board, each notified the Board of Pacira BioSciences, Inc. (the “Company”) of his respective decision to resign as a member of the Board, in each case, effective immediately”
Daryl Gaugler was named as Executive Vice President, Commercial Operations at Pacira BioSciences, Inc..
“On January 16, 2025, Daryl Gaugler was named Executive Vice President, Commercial Operations, instead of his former title as Chief Operating Officer.”
Brendan Teehan was appointed as Chief Commercial Officer at Pacira BioSciences, Inc..
“On January 16, 2025, Brendan Teehan was appointed Chief Commercial Officer of Pacira BioSciences, Inc. (the “Company”), effective January 21, 2025.”
Lauren Riker changed role as Senior Vice President of Finance at Pacira BioSciences, Inc..
“Mr. Cross will succeed Lauren Riker, who had been serving as interim Chief Financial Officer since October 1, 2024.”
Shawn M. Cross was appointed as Chief Financial Officer at Pacira BioSciences, Inc..
“appointed Shawn M. Cross to serve as the Chief Financial Officer of the Company, effective October 21, 2024.”
Lauren Riker was appointed as interim Chief Financial Officer at Pacira BioSciences, Inc..
“On September 26, 2024, the Board of Directors of the Company (the “Board”) appointed Lauren Riker, the Company’s current Senior Vice President of Finance and principal accounting officer, to also serve as interim Chief Financial Officer of the Company (including as principal financial officer and continuing as principal accounting officer for Securities and Exchange Commission reporting purposes), effective October 1, 2024.”
Charles A. Reinhart, III departed as Chief Financial Officer at Pacira BioSciences, Inc..
“Charles A. Reinhart, III, the Company’s Chief Financial Officer, agreed that he would depart the Company effective September 30, 2024, and will continue to serve as consultant to the Company for a period of nine months thereafter.”
Gary Pace departed as Director at Pacira BioSciences, Inc..
“On June 11, 2024, Gary Pace notified the Board of Directors (the “Board”) of Pacira BioSciences, Inc. (the “Company”) of his intent to retire from the Board, effective June 30, 2024.”
Pacira BioSciences, Inc. incurred convertible notes of up to an additional $37.5 million aggregate principal amount of the Notes with Jefferies LLC and J.P. Morgan Securities LLC, as representatives of the several initial purchasers at 2.125% per year maturing May 15, 2029.
“the Company granted the Initial Purchasers an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $37.5 million aggregate principal amount of the Notes on the same terms and conditions, which option was exercised in full by the Initial Purchasers on May 10, 2024.”
Pacira BioSciences, Inc. entered into Indenture with Computershare Trust Company, National Association, as trustee valued at 2.125% Convertible Senior Notes due 2029 (effective 2024-05-14).
“On May 14, 2024, the Company entered into an Indenture relating to the issuance of the Notes (the “Indenture”), by and between the Company and Computershare Trust Company, National Association, as trustee (the “Trustee”).”
Pacira BioSciences, Inc. entered into Purchase Agreement with Jefferies LLC and J.P. Morgan Securities LLC, as representatives of the several initial purchasers named therein valued at $250.0 million principal amount of its 2.125% Convertible Senior Notes due 2029 (effective 2024-05-09).
“On May 9, 2024, Pacira BioSciences, Inc. (the “Company”) entered into a purchase agreement (the “Purchase Agreement”) with Jefferies LLC and J.P. Morgan Securities LLC, as representatives of the several initial purchasers named therein (collectively, the “Initial Purchasers”), to issue and sell $250.0 million principal amount of its 2.125% Convertible Senior Notes due 2029”
Pacira BioSciences, Inc. amended First TLA Amendment with JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders (effective 2024-05-08).
“On May 8, 2024, Pacira BioSciences, Inc. (the “Company”), JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders entered into a first amendment (the “First TLA Amendment”) to the Credit Agreement, dated as of March 31, 2023”
Pacira BioSciences, Inc. reported first quarter ended March 31, 2024 results: revenue $167.1 million, net income $9.0 million, EPS $0.19 per share (basic and diluted).
“First Quarter 2024 Financial Highlights • Total revenues of $167.1 million • Net product sales of $132.4 million for EXPAREL, $25.8 million for ZILRETTA, and $5.0 million for iovera° • Net income of $9.0 million, or $0.19 per share (basic and diluted)”
Pacira BioSciences, Inc. reported fourth quarter and full-year ended December 31, 2023 results: revenue $675.0 million, net income $42.0 million, EPS $0.91 per basic share and $0.89 per diluted share.
“a filing. --- EX-99.1 (EX-99.1) --- NEWS RELEASE FOR IMMEDIATE RELEASE Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results — Record revenues of $675 million in 2023 — — Full-year GAAP net income of $42 million and adjusted EBITDA of $214 million — — EXPAREL surpasses the 14 million patient mark — — Conference call today at 8:30 a.m.”
Charles A. Reinhart, III departed as Chief Financial Officer at Pacira BioSciences, Inc..
“On February 26, 2024, the Company and Charles A. Reinhart, III, the Company’s Chief Financial Officer, agreed that he will depart the Company, effective September 30, 2024 (the “Transition Date”).”
Pacira BioSciences, Inc. reported preliminary financial results for fourth quarter ended December 31, 2023.
“On January 4, 2024, Pacira BioSciences, Inc. issued a press release announcing its preliminary unaudited revenue for the fourth quarter and full-year ended December 31, 2023”
Pacira BioSciences, Inc. reported full-year ended December 31, 2023 results: revenue $675.0 million.
“Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited total revenue of $675.0 million for the year ended December 31, 2023”
Frank Lee was appointed as Chief Executive Officer at Pacira BioSciences, Inc..
“the Board appointed Frank Lee as Chief Executive Officer of the Company and as a member of the Board, effective January 2, 2024.”
David Stack retired as Chief Executive Officer at Pacira BioSciences, Inc..
“David Stack informed the Board of Directors (the "Board") of Pacira BioSciences, Inc. (the "Company") that he intended to retire as Chief Executive Officer of the Company and as a member of the Board effective immediately following the appointment of his successor as Chief Executive Officer.”
Pacira BioSciences, Inc. reported full-year 2023 results: revenue EXPAREL net product sales of $535 million to $540 million. Guidance lowered.
“Pacira now expects full-year EXPAREL net product sales of $535 million to $540 million versus the company's previously guided range of $550 million to $560 million.”
Pacira BioSciences, Inc. reported financial results for third quarter of 2023.
“Total revenues were $163.9 million in the third quarter of 2023, versus $167.5 million reported for the third quarter of 2022.”
Michael Yang was appointed as Director at Pacira BioSciences, Inc..
“appointed each of Alethia Young, Marcelo Bigal, Abraham Ceesay and Michael Yang as a member of the Board”
Abraham Ceesay was appointed as Director at Pacira BioSciences, Inc..
“appointed each of Alethia Young, Marcelo Bigal, Abraham Ceesay and Michael Yang as a member of the Board”
Marcelo Bigal was appointed as Director at Pacira BioSciences, Inc..
“appointed each of Alethia Young, Marcelo Bigal, Abraham Ceesay and Michael Yang as a member of the Board”
Alethia Young was appointed as Director at Pacira BioSciences, Inc..
“appointed each of Alethia Young, Marcelo Bigal, Abraham Ceesay and Michael Yang as a member of the Board”
David Stack departed as Chief Executive Officer at Pacira BioSciences, Inc..
“David Stack informed the Board of Directors (the "Board") of Pacira BioSciences, Inc. (the "Company") that he intends to retire as Chief Executive Officer of the Company and as a member of the Board effective immediately following the appointment of his successor as Chief Executive Officer in order to ensure a smooth transition of leadership.”
Pacira BioSciences, Inc. updated its full year 2023 guidance (lowered).
“Pacira is revising the following full-year financial guidance: • EXPAREL net product sales of $550 million to $560 million versus the company’s previously guided range of $570 million to $580 million; • ZILRETTA net product sales of $110 million to $115 million versus the company’s previously guided range of $115 million to $125 million; • Non-GAAP gross margin of 73% to 74% versus the company’s previously guided range of 76% to 78%; and • Stock-based compensation of $46 million to $49 million versus the company’s previously guided range of $51 million to $54 million.”
Pacira BioSciences, Inc. reported the second quarter ended June 30, 2023 results: revenue Total revenues of $169.5 million, net income Net income of $25.8 million, EPS $0.56 per share (basic) and $0.51 per share (diluted). Guidance lowered.
“Total revenues of $169.5 million • Net product sales of $135.1 million for EXPAREL, $29.3 million for ZILRETTA, and $4.4 million for iovera° • Net income of $25.8 million, or $0.56 per share (basic) and $0.51 per share (diluted)”
Pacira BioSciences, Inc. shareholders approved Approval of the Company's Amended and Restated 2011 Stock Incentive Plan at the 2023-06-13 meeting.
“Proposal 4 — Approval of the Company’s Amended and Restated 2011 Stock Incentive Plan. For Against Abstain Broker Non-Votes 24,138,558 15,817,929 54,228 2,156,595”
Pacira BioSciences, Inc. shareholders approved Advisory vote to approve the compensation of the Company's named executive officers at the 2023-06-13 meeting.
“Proposal 3 — Advisory vote to approve the compensation of the Company’s named executive officers. For Against Abstain Broker Non-Votes 34,600,749 5,320,960 89,006 2,156,595”
Pacira BioSciences, Inc. shareholders approved Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-13 meeting.
“Proposal 2 — Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. For Against Abstain 41,872,540 282,024 12,746”
Pacira BioSciences, Inc. shareholders approved Election of three Class III directors to hold office until the 2026 Annual Meeting of Stockholders at the 2023-06-13 meeting.
“Proposal 1 — Election of three Class III directors to hold office until the 2026 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified. Nominee: For Withhold Broker Non-Votes Christopher Christie 39,024,151 986,564 2,156,595 Gary Pace 16,140,036 23,870,679 2,156,595 David Stack 38,008,964 2,001,751 2,156,595”
Pacira BioSciences, Inc. reported the first quarter of 2023 results: revenue $160.3 million, net income $19.5 million, EPS $0.43 per share (basic and diluted). Guidance reaffirmed.
“pain management and regenerative health solutions, today reported financial results for the first quarter of 2023. First Quarter 2023 Financial Highlights • Total revenues of $160.3 million • Net product sales of $130.4 million for EXPAREL, $24.3 million for ZILRETTA, and $4.0 million for iovera° • Net loss of $19.5 million, or $0.43 per share (basic and diluted) •”
Pacira BioSciences, Inc. incurred credit facility of $150.0 million with JPMorgan Chase Bank, N.A., as administrative agent and certain lenders at Alternate Base Rate plus a spread ranging from 2.00% to 2.75% maturing March 31, 2028.
“The Credit Agreement provides for a single-advance term loan A facility in the principal amount of $150.0 million, which is secured by substantially all of the Company's and any subsidiary guarantor's assets and is scheduled to mature on March 31, 2028”
Pacira BioSciences, Inc. terminated Existing Credit Agreement (effective 2023-03-31).
“On March 31, 2023, the Company used the $150.0 million of borrowings, together with cash on hand, to repay the indebtedness outstanding under the Existing Credit Agreement and terminated the Existing Credit Agreement.”
Pacira BioSciences, Inc. entered into Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent and certain lenders valued at $150.0 million (effective 2023-03-31).
“On March 31, 2023, Pacira BioSciences, Inc. (the “Company”) entered into a credit agreement (the “Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent and certain lenders, to refinance the indebtedness outstanding under the Company’s credit agreement, dated as of December 7, 2021, relating to the Company’s term loan B facility (the “Existing Credit Agreement”).”
Yvonne Greenstreet departed as Director at Pacira BioSciences, Inc..
“On March 18, 2023, Yvonne Greenstreet notified the Board of Directors (the “Board”) of Pacira BioSciences, Inc. (the “Company”) of her intent to of her intent to retire from the Board, effective March 31, 2023.”
Pacira BioSciences, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $172.0 million, net income $10.1 million, EPS $0.22 per basic and diluted share.
“Full-year revenues of $666.8 million and fourth quarter revenues of $172.0 million. • Full-year GAAP net income of $15.9 million or $0.35 per basic share and $0.34 per diluted share. • Fourth quarter GAAP net loss of $10.1 million or $0.22 per basic and diluted share.”
Pacira BioSciences, Inc. reported the full-year ended December 31, 2022 results: revenue $666.8 million, net income $15.9 million, EPS $0.35 per basic share and $0.34 per diluted share.
“Full-year revenues of $666.8 million and fourth quarter revenues of $172.0 million. • Full-year GAAP net income of $15.9 million or $0.35 per basic share and $0.34 per diluted share.”
Pacira BioSciences, Inc. reported 2022 results: EPS adjusted earnings per share of at least $2.50.
“Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited total revenue of $666.8 million for 2022, compared with $541.5 million for 2021, representing an increase of 23.1 percent.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.